ID   PHAG1_HUMAN             Reviewed;         432 AA.
AC   Q9NWQ8; A8K1A3; Q2M1Z9; Q5BKU4; Q9NYK0;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 2.
DT   07-APR-2021, entry version 153.
DE   RecName: Full=Phosphoprotein associated with glycosphingolipid-enriched microdomains 1;
DE   AltName: Full=Csk-binding protein;
DE   AltName: Full=Transmembrane adapter protein PAG;
DE   AltName: Full=Transmembrane phosphoprotein Cbp;
GN   Name=PAG1; Synonyms=CBP, PAG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 264-274, IDENTIFICATION BY
RP   MASS SPECTROMETRY, PHOSPHORYLATION AT TYR-317, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-37 AND CYS-40, MUTAGENESIS OF
RP   TYR-105; TYR-163; TYR-181; TYR-227; TYR-299; TYR-317; TYR-341; TYR-359;
RP   TYR-387 AND TYR-417, INTERACTION WITH FYN AND CSK, AND FUNCTION.
RX   PubMed=10790433; DOI=10.1084/jem.191.9.1591;
RA   Brdicka T., Pavlistova D., Bruyns E., Leo A., Korinek V., Angelisova P.,
RA   Scherer J., Shevchenko A., Shevchenko A., Hilgert I., Cerny J., Drbal K.,
RA   Kuramitsu Y., Horejsi V., Schraven B.;
RT   "Phosphoprotein associated with glycosphingolipid-enriched microdomains
RT   (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds
RT   the protein tyrosine kinase csk and is involved in regulation of T cell
RT   activation.";
RL   J. Exp. Med. 191:1591-1604(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Ileal mucosa;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=11684085; DOI=10.1016/s0014-5793(01)02955-6;
RA   Brdickova N., Brdicka T., Andera L., Spicka J., Angelisova P.,
RA   Milgram S.L., Horejsi V.;
RT   "Interaction between two adapter proteins, PAG and EBP50: a possible link
RT   between membrane rafts and actin cytoskeleton.";
RL   FEBS Lett. 507:133-136(2001).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=16160011; DOI=10.1182/blood-2005-06-2273;
RA   Tedoldi S., Paterson J.C., Hansmann M.-L., Natkunam Y., Rudiger T.,
RA   Angelisova P., Du M.Q., Roberton H., Roncador G., Sanchez L., Pozzobon M.,
RA   Masir N., Barry R., Pileri S., Mason D.Y., Marafioti T., Horejsi V.;
RT   "Transmembrane adaptor molecules: a new category of lymphoid-cell
RT   markers.";
RL   Blood 107:213-221(2006).
RN   [8]
RP   PHOSPHORYLATION AT TYR-317, INTERACTION WITH LYN AND STAT3, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18070987; DOI=10.1182/blood-2007-05-090985;
RA   Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D.,
RA   van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U., Borisch B.,
RA   Hoessli D.C.;
RT   "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine
RT   kinase in human B-NHL rafts.";
RL   Blood 111:2310-2320(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-227; SER-229; TYR-317;
RP   TYR-359; TYR-387 AND TYR-417, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
CC   -!- FUNCTION: Negatively regulates TCR (T-cell antigen receptor)-mediated
CC       signaling in T-cells and FCER1 (high affinity immunoglobulin epsilon
CC       receptor)-mediated signaling in mast cells. Promotes CSK activation and
CC       recruitment to lipid rafts, which results in LCK inhibition. Inhibits
CC       immunological synapse formation by preventing dynamic arrangement of
CC       lipid raft proteins. May be involved in cell adhesion signaling.
CC       {ECO:0000269|PubMed:10790433}.
CC   -!- SUBUNIT: Interacts with FYN. When phosphorylated, interacts with CSK.
CC       Interacts with SLC9A3R1/EBP50. In resting T-cells, part of a PAG1-
CC       SLC9A3R1-MSN complex which is disrupted upon TCR activation. Interacts
CC       with LYN on plasma membrane lipid rafts. Identified in a complex with
CC       LYN and STAT3. {ECO:0000269|PubMed:10790433,
CC       ECO:0000269|PubMed:11684085, ECO:0000269|PubMed:18070987}.
CC   -!- INTERACTION:
CC       Q9NWQ8; P41240: CSK; NbExp=4; IntAct=EBI-2828115, EBI-1380630;
CC       Q9NWQ8; P06241: FYN; NbExp=5; IntAct=EBI-2828115, EBI-515315;
CC       Q9NWQ8; P07948: LYN; NbExp=16; IntAct=EBI-2828115, EBI-79452;
CC       Q9NWQ8; P63244: RACK1; NbExp=2; IntAct=EBI-2828115, EBI-296739;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10790433,
CC       ECO:0000269|PubMed:18070987}; Single-pass type III membrane protein
CC       {ECO:0000269|PubMed:10790433, ECO:0000269|PubMed:18070987}.
CC       Note=Present in lipid rafts.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Present in germinal center
CC       B-cells, plasma cells, T-cells, monocytes and platelets (at protein
CC       level). {ECO:0000269|PubMed:10790433, ECO:0000269|PubMed:16160011}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:10790433}.
CC   -!- PTM: Phosphorylated by FYN on Tyr-317 in resting T-cells; which
CC       promotes interaction with CSK. Dephosphorylated by PTPRC/CD45 upon TCR
CC       activation; which leads to CSK dissociation. May also be
CC       dephosphorylated by PTPN11. Hyperphosphorylated in mast cells upon
CC       FCER1 activation. Phosphorylated by LYN. {ECO:0000269|PubMed:10790433,
CC       ECO:0000269|PubMed:18070987}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF240634; AAF67343.1; -; mRNA.
DR   EMBL; AK000680; BAA91321.1; -; mRNA.
DR   EMBL; AK289818; BAF82507.1; -; mRNA.
DR   EMBL; CH471068; EAW87086.1; -; Genomic_DNA.
DR   EMBL; BC090931; AAH90931.1; -; mRNA.
DR   EMBL; BC112159; AAI12160.1; -; mRNA.
DR   CCDS; CCDS6227.1; -.
DR   RefSeq; NP_060910.3; NM_018440.3.
DR   RefSeq; XP_016869129.1; XM_017013640.1.
DR   RefSeq; XP_016869130.1; XM_017013641.1.
DR   RefSeq; XP_016869131.1; XM_017013642.1.
DR   RefSeq; XP_016869132.1; XM_017013643.1.
DR   SMR; Q9NWQ8; -.
DR   BioGRID; 120931; 47.
DR   CORUM; Q9NWQ8; -.
DR   IntAct; Q9NWQ8; 47.
DR   MINT; Q9NWQ8; -.
DR   STRING; 9606.ENSP00000220597; -.
DR   iPTMnet; Q9NWQ8; -.
DR   PhosphoSitePlus; Q9NWQ8; -.
DR   SwissPalm; Q9NWQ8; -.
DR   BioMuta; PAG1; -.
DR   DMDM; 84029384; -.
DR   EPD; Q9NWQ8; -.
DR   jPOST; Q9NWQ8; -.
DR   MassIVE; Q9NWQ8; -.
DR   MaxQB; Q9NWQ8; -.
DR   PaxDb; Q9NWQ8; -.
DR   PeptideAtlas; Q9NWQ8; -.
DR   PRIDE; Q9NWQ8; -.
DR   ProteomicsDB; 82961; -.
DR   TopDownProteomics; Q9NWQ8; -.
DR   Antibodypedia; 1175; 359 antibodies.
DR   DNASU; 55824; -.
DR   Ensembl; ENST00000220597; ENSP00000220597; ENSG00000076641.
DR   GeneID; 55824; -.
DR   KEGG; hsa:55824; -.
DR   UCSC; uc003ybz.4; human.
DR   CTD; 55824; -.
DR   DisGeNET; 55824; -.
DR   GeneCards; PAG1; -.
DR   HGNC; HGNC:30043; PAG1.
DR   HPA; ENSG00000076641; Low tissue specificity.
DR   MIM; 605767; gene.
DR   neXtProt; NX_Q9NWQ8; -.
DR   OpenTargets; ENSG00000076641; -.
DR   PharmGKB; PA142671201; -.
DR   VEuPathDB; HostDB:ENSG00000076641.4; -.
DR   eggNOG; ENOG502QUCZ; Eukaryota.
DR   GeneTree; ENSGT00390000002061; -.
DR   HOGENOM; CLU_051189_1_0_1; -.
DR   InParanoid; Q9NWQ8; -.
DR   OMA; QCRDITR; -.
DR   OrthoDB; 1104680at2759; -.
DR   PhylomeDB; Q9NWQ8; -.
DR   TreeFam; TF336170; -.
DR   PathwayCommons; Q9NWQ8; -.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   SignaLink; Q9NWQ8; -.
DR   BioGRID-ORCS; 55824; 15 hits in 988 CRISPR screens.
DR   ChiTaRS; PAG1; human.
DR   GeneWiki; PAG1; -.
DR   GenomeRNAi; 55824; -.
DR   Pharos; Q9NWQ8; Tbio.
DR   PRO; PR:Q9NWQ8; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q9NWQ8; protein.
DR   Bgee; ENSG00000076641; Expressed in secondary oocyte and 216 other tissues.
DR   Genevisible; Q9NWQ8; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; IDA:HGNC-UCL.
DR   GO; GO:0035591; F:signaling adaptor activity; NAS:HGNC-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:HGNC-UCL.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IBA:GO_Central.
DR   GO; GO:0050863; P:regulation of T cell activation; IDA:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR032748; PAG.
DR   PANTHER; PTHR16322; PTHR16322; 1.
DR   Pfam; PF15347; PAG; 1.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Cell membrane; Direct protein sequencing; Immunity;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Reference proteome;
KW   Signal-anchor; Transmembrane; Transmembrane helix.
FT   CHAIN           1..432
FT                   /note="Phosphoprotein associated with glycosphingolipid-
FT                   enriched microdomains 1"
FT                   /id="PRO_0000083338"
FT   TOPO_DOM        1..16
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        17..37
FT                   /note="Helical; Signal-anchor for type III membrane
FT                   protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        38..432
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          317..320
FT                   /note="Interaction with CSK"
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   REGION          430..432
FT                   /note="Interaction with SLC9A3R1"
FT                   /evidence="ECO:0000269|PubMed:11684085"
FT   MOD_RES         50
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JM80"
FT   MOD_RES         61
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JM80"
FT   MOD_RES         105
FT                   /note="Phosphotyrosine; by LYN"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JM80"
FT   MOD_RES         163
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U1F9"
FT   MOD_RES         181
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U1F9"
FT   MOD_RES         227
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         229
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         317
FT                   /note="Phosphotyrosine; by FYN and LYN"
FT                   /evidence="ECO:0000269|PubMed:10790433,
FT                   ECO:0000269|PubMed:18070987, ECO:0007744|PubMed:19690332"
FT   MOD_RES         354
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U1F9"
FT   MOD_RES         359
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3U1F9"
FT   MOD_RES         387
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         417
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   LIPID           37
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:10790433"
FT   LIPID           40
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:10790433"
FT   MUTAGEN         105
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         163
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         181
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         227
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         299
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         317
FT                   /note="Y->F: No effect on interaction with FYN. Abolishes
FT                   interaction with CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         341
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         359
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         387
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   MUTAGEN         417
FT                   /note="Y->F: No effect on interaction with FYN or CSK."
FT                   /evidence="ECO:0000269|PubMed:10790433"
FT   CONFLICT        4
FT                   /note="A -> V (in Ref. 4; AAH90931)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        36
FT                   /note="L -> P (in Ref. 2; BAA91321)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   432 AA;  46981 MW;  E86272A0B7E3328C CRC64;
     MGPAGSLLGS GQMQITLWGS LAAVAIFFVI TFLIFLCSSC DREKKPRQHS GDHENLMNVP
     SDKEMFSRSV TSLATDAPAS SEQNGALTNG DILSEDSTLT CMQHYEEVQT SASDLLDSQD
     STGKPKCHQS RELPRIPPES AVDTMLTARS VDGDQGLGME GPYEVLKDSS SQENMVEDCL
     YETVKEIKEV AAAAHLEKGH SGKAKSTSAS KELPGPQTEG KAEFAEYASV DRNKKCRQSV
     NVESILGNSC DPEEEAPPPV PVKLLDENEN LQEKEGGEAE ESATDTTSET NKRFSSLSYK
     SREEDPTLTE EEISAMYSSV NKPGQLVNKS GQSLTVPEST YTSIQGDPQR SPSSCNDLYA
     TVKDFEKTPN STLPPAGRPS EEPEPDYEAI QTLNREEEKA TLGTNGHHGL VPKENDYESI
     SDLQQGRDIT RL
//
